These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38142321)

  • 21. Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort.
    Bjerrum A; Lindebjerg J; Andersen O; Fischer A; Lynge E
    Int J Cancer; 2020 Aug; 147(4):940-947. PubMed ID: 31894860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening.
    Hubbard RA; Johnson E; Hsia R; Rutter CM
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1612-9. PubMed ID: 23868091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
    Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
    Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
    D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
    Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yield of repeat colonoscopy in asymptomatic individuals with a positive fecal immunochemical test and recent colonoscopy.
    Kim NH; Jung YS; Lim JW; Park JH; Park DI; Sohn CI
    Gastrointest Endosc; 2019 May; 89(5):1037-1043. PubMed ID: 30684602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates and correlates of potentially inappropriate colorectal cancer screening in the Veterans Health Administration.
    Powell AA; Saini SD; Breitenstein MK; Noorbaloochi S; Cutting A; Fisher DA; Bloomfield HE; Halek K; Partin MR
    J Gen Intern Med; 2015 Jun; 30(6):732-41. PubMed ID: 25605531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
    Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
    Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
    Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
    World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
    Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
    Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province.
    Parente F; Marino B; Ardizzoia A; Ucci G; Ilardo A; Limonta F; Villani P; Moretti R; Zucchi A; Cremaschini M; Pirola ME
    Am J Gastroenterol; 2011 Nov; 106(11):1986-93. PubMed ID: 21670773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
    Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
    Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
    [No Abstract]   [Full Text] [Related]  

  • 33. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
    Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
    J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model based evaluation of long-term efficacy of existing and alternative colorectal cancer screening offers: A case study for Germany.
    Heisser T; Hoffmeister M; Brenner H
    Int J Cancer; 2022 May; 150(9):1471-1480. PubMed ID: 34888862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
    Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
    Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in colonoscopy and fecal occult blood test use after the introduction of dual screening offers in Germany: Results from a large population-based study, 2003-2016.
    Chen C; Stock C; Jansen L; Chang-Claude J; Hoffmeister M; Brenner H
    Prev Med; 2019 Jun; 123():333-340. PubMed ID: 30946858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
    Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
    Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.